A regulatory non-interventional study to monitor the safety and efficacy of JARDIANCE® (Empagliflozin 10 mg) in Korean patients with Chronic Kidney Disease (CKD)

ENCePP Code of conduct

No

Data sources

• Data sources (types):
  Electronic healthcare records (EHR)

  Other
• Data sources (types), other:
  The source data will be captured from the medical records of the patients who have consented to data release.

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  No
• Check completeness:
  No
• Check stability:
  No
• Check logical consistency:
  No

Data characterisation

• Data characterisation conducted:
  No